Rinvoq® (upadacitinib) – New indication
On January 14, 2022, AbbVie announced the FDA approval of Rinvoq (upadacitinib), for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable.
Top